A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models

Rabbit antibodies have been widely used in research and diagnostics due to their high antigen specificity and affinity. Though these properties are also highly desirable for therapeutic applications, rabbit antibodies have remained untapped for human disease therapy. To evaluate the therapeutic potential of rabbit monoclonal antibodies (RabMAbs), we generated a panel of neutralizing RabMAbs against human vascular endothelial growth factor-A (VEGF). These neutralizing RabMAbs are specific to VEGF and do not cross-react to other members of the VEGF protein family. Guided by sequence and lineage analysis of a panel of neutralizing RabMAbs, we humanized the lead candidate by substituting non-critical residues with human residues within both the frameworks and the CDR regions. We showed that the humanized RabMAb retained its parental biological properties and showed potent inhibition of the growth of H460 lung carcinoma and A673 rhabdomyosarcoma xenografts in mice. These studies provide proof of principle for the feasibility of developing humanized RabMAbs as therapeutics.

[1]  N. Lonberg.  Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[2]  S. Kaul,et al.  A Novel Alternatively Spliced Form of Murine Vascular Endothelial Growth Factor, VEGF 115* , 1998, The Journal of Biological Chemistry.

[3]  S. Rafii,et al.  Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.

[4]  T. Sitnikova,et al.  Coevolution of immunoglobulin heavy- and light-chain variable-region gene families. , 1998, Molecular biology and evolution.

[5]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[6]  R. Dillman,et al.  Monoclonal antibodies in cancer therapy: 25 years of progress. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[8]  T. Fukuda,et al.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma , 2000, Cancer.

[9]  E. Padlan,et al.  Anatomy of the antibody molecule. , 1994, Molecular immunology.

[10]  J. Bystryn,et al.  Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. , 1982, Hybridoma.

[11]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[12]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[13]  G. Litman,et al.  Genomic organization and sequences of immunoglobulin light chain genes in a primitive vertebrate suggest coevolution of immunoglobulin gene organization. , 1989, The EMBO journal.

[14]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[15]  P E Thorpe,et al.  Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. , 1998, Biochemical and biophysical research communications.

[16]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[17]  S. Loefas,et al.  Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. , 1991, Analytical biochemistry.

[18]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[19]  D. Christ,et al.  Selection of human antibody fragments by phage display , 2007, Nature Protocols.

[20]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  Zhida Huang,et al.  Development of New Rabbit Monoclonal Antibody to Progesterone Receptor (Clone SP2): No Heat Pretreatment but Effective for Paraffin Section Immunohistochemistry , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[22]  Peter Bohlen,et al.  Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity* , 2003, Journal of Biological Chemistry.

[23]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[24]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[26]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[27]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[28]  Zhiqiang An,et al.  Therapeutic monoclonal antibodies , 2009 .

[29]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[30]  Ida Retter,et al.  VBASE2, an integrative V gene database , 2004, Nucleic Acids Res..

[31]  A R Rees,et al.  Humanization of murine monoclonal antibodies through variable domain resurfacing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[33]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Ultsch,et al.  Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.

[35]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[36]  A. D. Dei Tos,et al.  Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. , 2005, American journal of clinical pathology.

[37]  K L Knight,et al.  Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[39]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[40]  F. Peale,et al.  Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.

[41]  T. T. Wu,et al.  Length distribution of CDRH3 in antibodies , 1993, Proteins.

[42]  D. J. Groves,et al.  Veterinary sources of nonrodent monoclonal antibodies: interspecific and intraspecific hybridomas. , 2000, Hybridoma.

[43]  E. Adamson,et al.  Preparation and properties of monoclonal and polyclonal antibodies to mouse epidermal growth factor (EGF) receptors: evidence for cryptic EGF receptors in embryonal carcinoma cells. , 1987, Development.

[44]  C. Barbas,et al.  Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. , 2003, Journal of molecular biology.

[45]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[46]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[47]  M. Omary,et al.  Bispecific and human disease-related anti-keratin rabbit monoclonal antibodies. , 2006, Experimental cell research.

[48]  E. Estey,et al.  Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. , 1999, Blood.

[49]  G. Fleuren,et al.  The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. , 1998, British Journal of Cancer.

[50]  O. Heidmann,et al.  Immunoglobulin κ light-chain diversity in rabbit is based on the 3′ length heterogeneity of germ-line variable genes , 1984, Nature.

[51]  Qinjian Zhao,et al.  Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. , 2005, Analytical biochemistry.

[52]  B. Terman,et al.  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization , 1999, Oncogene.

[53]  R. Amado,et al.  From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice , 2007, Nature Biotechnology.